JP6404338B2 - 抗体製剤および方法 - Google Patents

抗体製剤および方法 Download PDF

Info

Publication number
JP6404338B2
JP6404338B2 JP2016522950A JP2016522950A JP6404338B2 JP 6404338 B2 JP6404338 B2 JP 6404338B2 JP 2016522950 A JP2016522950 A JP 2016522950A JP 2016522950 A JP2016522950 A JP 2016522950A JP 6404338 B2 JP6404338 B2 JP 6404338B2
Authority
JP
Japan
Prior art keywords
antibody
seq
concentration
formulation
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016522950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534052A (ja
JP2016534052A5 (enExample
Inventor
ガリデル，パトリック
ランガー，アンドレアス
グランドマン，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothena Biosciences Ltd
Original Assignee
Neotope Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51355583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6404338(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neotope Biosciences Ltd filed Critical Neotope Biosciences Ltd
Publication of JP2016534052A publication Critical patent/JP2016534052A/ja
Publication of JP2016534052A5 publication Critical patent/JP2016534052A5/ja
Application granted granted Critical
Publication of JP6404338B2 publication Critical patent/JP6404338B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
JP2016522950A 2013-07-04 2014-07-03 抗体製剤および方法 Active JP6404338B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843011P 2013-07-04 2013-07-04
US61/843,011 2013-07-04
US201461979886P 2014-04-15 2014-04-15
US61/979,886 2014-04-15
PCT/IB2014/062806 WO2015001504A2 (en) 2013-07-04 2014-07-03 Antibody formulations and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018170393A Division JP6854266B2 (ja) 2013-07-04 2018-09-12 抗体製剤および方法

Publications (3)

Publication Number Publication Date
JP2016534052A JP2016534052A (ja) 2016-11-04
JP2016534052A5 JP2016534052A5 (enExample) 2017-08-10
JP6404338B2 true JP6404338B2 (ja) 2018-10-10

Family

ID=51355583

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016522950A Active JP6404338B2 (ja) 2013-07-04 2014-07-03 抗体製剤および方法
JP2018170393A Active JP6854266B2 (ja) 2013-07-04 2018-09-12 抗体製剤および方法
JP2020177954A Pending JP2021020941A (ja) 2013-07-04 2020-10-23 抗体製剤および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018170393A Active JP6854266B2 (ja) 2013-07-04 2018-09-12 抗体製剤および方法
JP2020177954A Pending JP2021020941A (ja) 2013-07-04 2020-10-23 抗体製剤および方法

Country Status (17)

Country Link
US (2) US10513555B2 (enExample)
EP (2) EP3524264A1 (enExample)
JP (3) JP6404338B2 (enExample)
KR (1) KR20160030247A (enExample)
CN (1) CN105492019B (enExample)
AU (1) AU2014285719A1 (enExample)
CA (1) CA2917097C (enExample)
CL (1) CL2015003801A1 (enExample)
CU (2) CU20170039A7 (enExample)
ES (1) ES2704440T3 (enExample)
IL (1) IL243425A0 (enExample)
MX (1) MX2016000201A (enExample)
PE (1) PE20160868A1 (enExample)
PH (1) PH12015502788A1 (enExample)
RU (1) RU2016103079A (enExample)
SG (1) SG11201510601TA (enExample)
WO (1) WO2015001504A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010198B1 (pt) 2011-10-28 2022-12-06 Prothena Biosciences Limited Anticorpos humanizados que reconhecem alfa-sinucleína
DK2807188T3 (da) 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015155694A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
DK3334747T5 (da) 2015-08-13 2024-10-07 Amgen Inc Ladet dybdefiltrering af antigenbindende proteiner
JP6921062B2 (ja) * 2015-09-28 2021-08-18 スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド 安定な抗ｐｄ−１抗体医薬製剤および医薬におけるその適用
CN105127166A (zh) * 2015-09-29 2015-12-09 中国华能集团清洁能源技术研究院有限公司 行走组件及具有其的光伏组件清洁装置
EP3909985A1 (en) * 2016-06-27 2021-11-17 MorphoSys AG Anti-cd19 antibody formulations
RU2019114679A (ru) * 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
CN110072888B (zh) 2016-12-16 2023-07-18 H.隆德贝克有限公司 药剂、用途和方法
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
WO2019064053A1 (en) * 2017-09-28 2019-04-04 Prothena Biosciences Limited DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES
US20190153102A1 (en) * 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
JP6831861B2 (ja) 2019-01-25 2021-02-17 株式会社Ｇｒｉｎ 歯科用測定器具、測定方法、及びアタッチメント器具
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
EP3786174A1 (en) * 2019-08-27 2021-03-03 Ichnos Sciences SA Methods for antibody purification
GB2587228B (en) * 2019-09-20 2021-10-27 Protein Ark Ltd Biological sample purification apparatus, use of the same, and systems comprising the same
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
JP2023541048A (ja) 2020-09-10 2023-09-27 プロシーナ バイオサイエンシーズ リミテッド パーキンソン病の処置
CN114516914B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒
CN117915952A (zh) 2021-09-16 2024-04-19 H.隆德贝克有限公司 用于治疗突触核蛋白病的组合物和方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE69620877T2 (de) 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE371231T1 (de) 1999-02-05 2007-09-15 Samsung Electronics Co Ltd Verfahren und vorrichtung zur wiederauffindung von texturbildern
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
DE60323474D1 (de) 2002-04-09 2008-10-23 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
CA2485342A1 (en) 2002-05-13 2004-05-13 Alexion Pharmaceuticals, Inc. Humanized antibodies against the venezuelan equine encephalitis virus
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
DK1567652T3 (da) 2002-11-29 2007-11-26 Boehringer Ingelheim Pharma Nye neomycin-phosphotransferasegener og fremgangsmåde til selektion af höjtproducerende rekombinante celler
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
CA2632519A1 (en) * 2005-12-06 2007-07-05 Amgen Inc. Polishing steps used in multi-step protein purification processes
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CN101663320A (zh) 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
SG182160A1 (en) 2007-03-02 2012-07-30 Boehringer Ingelheim Pharma Improvement of protein production
RS53402B (sr) 2007-03-22 2014-10-31 Genentech, Inc. Vezivanje apoptotskih anti-ige antitela za membranski ige
BRPI0809112A2 (pt) 2007-03-22 2014-08-26 Imclone Llc Formulações estáveis de anticorpos
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
AU2008340429C1 (en) 2007-12-21 2016-09-08 F. Hoffmann-La Roche Ag Antibody formulation
CN102016059B (zh) 2007-12-28 2014-10-22 依兰制药公司 淀粉样变性的治疗和预防
LT2282758T (lt) 2008-04-29 2019-03-12 Bioarctic Ab Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
NZ598156A (en) 2009-07-28 2014-06-27 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2519537A4 (en) 2009-12-29 2013-07-10 Reddys Lab Ltd Dr CLEANING PROTEINS
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011127324A2 (en) 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
CA2805112A1 (en) 2010-07-15 2012-01-19 Synovex Corporation Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
MX344268B (es) * 2010-10-11 2016-12-09 Abbvie Inc * Proceso para purificacion de proteinas.
US8741298B2 (en) 2011-02-07 2014-06-03 Neotope Biosciences Limited APOE immunotherapy
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
HK1198689A1 (en) * 2011-10-25 2015-05-29 Prothena Biosciences Limited Antibody formulations and methods
BR112014010198B1 (pt) 2011-10-28 2022-12-06 Prothena Biosciences Limited Anticorpos humanizados que reconhecem alfa-sinucleína
RS63948B1 (sr) 2011-10-31 2023-02-28 Hoffmann La Roche Formulacije anti-il13 antitela
DK2807188T3 (da) 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
KR20150039798A (ko) 2012-08-29 2015-04-13 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
US8925815B2 (en) 2012-09-05 2015-01-06 Symbol Technologies, Inc. Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015155694A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Also Published As

Publication number Publication date
JP2021020941A (ja) 2021-02-18
CU20160001A7 (es) 2016-08-31
CA2917097C (en) 2022-05-03
EP3016677B1 (en) 2018-12-19
PH12015502788A1 (en) 2016-03-21
WO2015001504A3 (en) 2015-08-06
CN105492019A (zh) 2016-04-13
EP3524264A1 (en) 2019-08-14
CL2015003801A1 (es) 2016-07-15
JP2016534052A (ja) 2016-11-04
AU2014285719A1 (en) 2016-01-21
WO2015001504A2 (en) 2015-01-08
CU20170039A7 (es) 2017-06-05
HK1223544A1 (zh) 2017-08-04
IL243425A0 (en) 2016-03-31
PE20160868A1 (es) 2016-09-24
SG11201510601TA (en) 2016-01-28
JP2019011339A (ja) 2019-01-24
ES2704440T3 (es) 2019-03-18
RU2016103079A (ru) 2017-08-07
US20200140534A1 (en) 2020-05-07
KR20160030247A (ko) 2016-03-16
CN105492019B (zh) 2020-02-11
MX2016000201A (es) 2016-05-31
JP6854266B2 (ja) 2021-04-07
CA2917097A1 (en) 2015-01-08
US10513555B2 (en) 2019-12-24
US20150079074A1 (en) 2015-03-19
EP3016677A2 (en) 2016-05-11

Similar Documents

Publication Publication Date Title
JP6404338B2 (ja) 抗体製剤および方法
JP6007316B2 (ja) 抗体製剤
AU2013305885B2 (en) Molecules with antigen binding and polyvalent Fc gamma receptor binding activity
TWI711631B (zh) 抗甲狀腺素運送蛋白抗體
US12384822B2 (en) TAM receptor-binding fusion molecule having non-inflammatory phagocytosis inducing activity
JP2020011978A (ja) 便秘症状からのレビー小体病の免疫療法のモニター
JP7477457B2 (ja) Ｃ３結合薬及びその使用方法
EP4582445A1 (en) Anti-human complement c5 antibody and fusion protein thereof
HK40005408A (en) Antibody purification method
HK1223544B (zh) 抗体制剂和方法
EP3808847A1 (en) Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof
EP4631975A1 (en) Fusion comprising anti-tau antibody and peptide and use thereof
RU2802307C2 (ru) C3-связывающие агенты и способы их применения
TW201628648A (zh) 纖維變性疾病之治療
CA3276286A1 (en) Fusion comprising anti-tau antibody and peptide and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180821

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180912

R150 Certificate of patent or registration of utility model

Ref document number: 6404338

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250